The Biomedical Advanced Research and Development Authority (BARDA) and Beckman Coulter are joining forces to fund a multi-center clinical trial of Beckman Coulter’s Monocyte Distribution Width (MDW) hematology biomarker, a test meant to rapidly detect MIS-C.
MIS-C, or Multisystem Inflammatory Syndrome in Children, is a rare but dangerous post-COVID-19 condition that has complicated recovery among more than 1,000 children in the U.S. Untreated, it can cause hypotensive shock, cardiac aneurysms, or ventricular failure — and that’s just in the short term. It’s too early to know its long-term effects. It’s also hard to pin down since its initial symptoms are merely mild things like fevers or rashes.
Worse, there are currently no tests for MIS-C, and cases could increase now that more children are crowded together again for school.
Enter: Beckman Coulter. Beckman Coulter’s MDW biomarker has already been cleared by the Food and Drug Administration (FDA) as a marker of sepsis among adults. It’s already used in emergency departments, and preliminary results from a Massachusetts General Hospital study have shown that it could assist in the rapid detection of MIS-C as well.
The new effort will be collaborative, and beyond Beckman Coulter, will include partners at Massachusetts General Hospital, Johns Hopkins University School of Medicine, and the University of Florida. If a trial proves successful, they will seek regulatory approval for the biomarker’s use on MIS-C.
Members of Congress recently paraded a mix of recommended updates to benefit military service members…
The ByteDance-owned TikTok faces an uphill battle in the United States after President Joe Biden…
Promising to grow space for integrating and delivering on critical defense programs by more than…
In unsealing a 13-page indictment this week, the U.S. Department of Justice (DOJ) revealed charges…
A bill targeting the illicit fentanyl supply chain, the Fentanyl Eradication and Narcotics Deterrence (FEND)…
In order to move the state closer to federal standards and allow reporting of local…
This website uses cookies.